Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial (Q34264876)

1 August 2017

title

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial (English)

1 reference

1 August 2017

2

George A Wells

1 reference

1 August 2017

6

Michael Froeschl

1 reference

1 August 2017

4

Marino Labinaz

1 reference

1 August 2017

7

Alexander Dick

1 reference

1 August 2017

Jean-François Marquis

8

object named as

Jean-Francois Marquis

1 reference

1 August 2017

3

Michel R Le May

1 reference

1 August 2017

Jason D Roberts

1

1 reference

1 August 2017

Chris Glover

5

1 reference

1 August 2017

Edward O'Brien

9

1 reference

1 August 2017

Sandro Goncalves

10

1 reference

1 August 2017

Irena Druce

11

1 reference

1 August 2017

Alexandre Stewart

12

1 reference

1 August 2017

Michael H Gollob

13

1 reference

1 August 2017

Derek Y F So

14

1 reference

1 August 2017

language of work or name

English

0 references

publication date

29 March 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

379

1 reference

1 August 2017

issue

9827

1 reference

1 August 2017

page(s)

1705-1711

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genomics and drug response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Paraoxonase-1 is a major determinant of clopidogrel efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Can we override clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960161-5

7 January 2021

10.1016/S0140-6736(12)60161-5

Identifiers

DOI

1 reference

release_kyyjxzajijhvpch74abfkelqmu

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kyyjxzajijhvpch74abfkelqmu

24 November 2022

mapped directly with Wikidata item

1 reference